Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-28
2006-02-28
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S256000, C544S327000, C544S328000, C544S329000
Reexamination Certificate
active
07005433
ABSTRACT:
Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
REFERENCES:
patent: 4018913 (1977-04-01), Okamoto et al.
patent: 4018915 (1977-04-01), Okamoto et al.
patent: 4036955 (1977-07-01), Okamoto et al.
patent: 4041156 (1977-08-01), Okamoto et al.
patent: 4046876 (1977-09-01), Okamoto et al.
patent: 4055636 (1977-10-01), Okamoto et al.
patent: 4055651 (1977-10-01), Okamoto et al.
patent: 4070457 (1978-01-01), Okamoto et al.
patent: 4073914 (1978-02-01), Kikumoto et al.
patent: 4085057 (1978-04-01), Masuda et al.
patent: 4096255 (1978-06-01), Kikumoto et al.
patent: 4104392 (1978-08-01), Okamoto et al.
patent: 4438122 (1984-03-01), Holmwood et al.
patent: 4505910 (1985-03-01), Bagli
patent: 4518600 (1985-05-01), Holmwood et al.
patent: 4544402 (1985-10-01), Schnurbusch et al.
patent: 4559345 (1985-12-01), Gomarasca et al.
patent: 4672065 (1987-06-01), Spatz
patent: 4908368 (1990-03-01), Murase et al.
patent: 4959364 (1990-09-01), Mueller et al.
patent: 4992439 (1991-02-01), Meanwell
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5120734 (1992-06-01), Klausener et al.
patent: 5238934 (1993-08-01), Knuppel et al.
patent: 5278184 (1994-01-01), Artico et al.
patent: 5510332 (1996-04-01), Kogan et al.
patent: 5580868 (1996-12-01), Lunkenheimer et al.
patent: 5770573 (1998-06-01), Arrhenius et al.
patent: 5814643 (1998-09-01), Duggan et al.
patent: 5861429 (1999-01-01), Sato et al.
patent: 5925644 (1999-07-01), Jakobi et al.
patent: 5942504 (1999-08-01), Grobelny
patent: 5955491 (1999-09-01), Sohda et al.
patent: 5962479 (1999-10-01), Chen
patent: 5972946 (1999-10-01), Murata et al.
patent: 6005117 (1999-12-01), Wehner et al.
patent: 6492372 (2002-12-01), Konradi et al.
patent: 2002/0052375 (2002-05-01), Konradi et al.
patent: 2002/0055509 (2002-05-01), Konradi et al.
patent: 2003/0144328 (2003-07-01), Konradi et al.
patent: 2241149 (1977-07-01), None
patent: 2259224 (1978-01-01), None
patent: 2655636 (1977-06-01), None
patent: 19536891 (1997-04-01), None
patent: 19548709 (1997-07-01), None
patent: 19654483 (1998-01-01), None
patent: 19713000 (1998-10-01), None
patent: 0 116 494 (1984-08-01), None
patent: 0 288 176 (1988-10-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 330 506 (1989-08-01), None
patent: 0 526 348 (1993-02-01), None
patent: 0 535 521 (1993-04-01), None
patent: 0 147 211 (1993-07-01), None
patent: 1500063 (1978-02-01), None
patent: 169926 (1976-09-01), None
patent: 59212480 (1984-12-01), None
patent: 92/16549 (1992-10-01), None
patent: 93/12809 (1993-07-01), None
patent: 96/01644 (1996-01-01), None
patent: 96/22966 (1996-08-01), None
patent: 96/32383 (1997-04-01), None
patent: 97/23451 (1997-07-01), None
patent: 98/00395 (1998-01-01), None
patent: 98/53817 (1998-08-01), None
patent: 98/33783 (1998-12-01), None
patent: 98/53814 (1998-12-01), None
patent: 99/06390 (1999-02-01), None
patent: 99/06391 (1999-02-01), None
patent: 99/06431 (1999-02-01), None
patent: 99/06432 (1999-02-01), None
patent: 99/06433 (1999-02-01), None
patent: 99/10312 (1999-03-01), None
patent: 99/10313 (1999-03-01), None
patent: 99/37605 (1999-07-01), None
patent: 99/37618 (1999-07-01), None
patent: 99/52898 (1999-10-01), None
U.S. Appl. No. 10/251,442, filed Sep. 20, 2002.
Abraham, et al. “Alpha4-Integrins Mediate Antigen-Induced Late Bronchial Responses and Prolonges Airway Hyperresponsiveness in Sheep,”J. Clin. Invest. 93: 776-787 (1994).
Advani, S.B., et al. “Potential Antineoplastic Agents: N-(1-Benzoxazolyl)amino Acid Esters,”J. Pharm. Sci. 57(10): 1693-1696 (1968).
Bao, et al. “Correlation of VLA-4 Integrin Expression with Metastatic Potential In Various Human Tumor Cell Lines,”Diff. 52: 239-246 (1993).
Baron, et al. “Surface Expression of α4 Integrin by CD4 T Cells is Required for Their Entry into Brain Parenchyma,”J. Exp. Med. 177: 57-68 (1993).
Baron, et al. “The Pathogensis of Adoptive Murine Autoimmune Diabetes Required an Interaction between α4-Integrins and Vascular Cell Adhesion Molecule-1,”J. Clin. Invest. 93: 1700-1708 (1994).
Burkly, et al. “Protection Against Adoptive Transfer of Autoimmune Diabetes Mediated Through Very Late Antigen-4 Integrin,”Diabetes43: 529-534 (1994).
Cybulsky, et al. “Endothelial Expression of a Monomuclear Leukocyte Adhesion Molecule during Atherogenesis,”Science251: 788-791 (1991).
Elices, et al. “Expression and Functional Significance of Alternatively Spliced CS1 Fibronectin in Rhematoid Arthritis Microvasculature,”J. Clin. Invest. 93: 405-416 (1994).
Elices, et al. “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrim VLA-4 at a Site Distinct from the VLA-4/Fibronectin Binding Site,”Cell60: 577-584 (1990).
Gordeev, M.F., et al. “Combinatorial Approaches to Pharmacophoric Heterocycles: A Solid-Phase Synthesis of 3, 1-Benzoxazine-4-ones,”Biotech. And Bioengineering61(1): 13-16 (1998).
Hamann, et al. “Role of α4-Integrins in Lymphocyte Homing to Mucosal Tissues In Vivo,”J. Immunol. 152: 3283-3292 (1994).
Henke, B.R., et al. “N-(2-Benzoylphenyl)-L-tyrosine: Aryl Agonists. Disclovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents,”J. Med. Chem. 41(25): 5020-5036 (1998).
Hladon, B., et al. “In Vitro cytostatic activity of some amino acid 4-N-subsitited cytosines,”Arch. Immunol. Ther. Exp. 40(2): 145-150 (1992 (Abstract).
Hoffman, S., et al. N-Pyrimidinylamino acids, III. N-(oxopyrimidinyl) derivatives of neutral amino acids.Z. Chem. 12(1): 21-22 (1972). Coden: Zeaceal. (Abstract).
Jaeger, et al.Chem. Berichte. 101(8): 2762-2770 (1968). Chem. Abstract 69: 676 Kawaguchi, et al. “VLA-4 Molecules on tumor Cells Initiate an Adhesive Interaction with VCAM-1 Molecules on Endothelial Cell Surface,”Jap. J. Canc. Res. 83: 1304-1316 (1992).
Lauri, et al. “Decreased Adhesion to Endothelial Cells and Matrix of H-2KbGene Transfected Tumor Cells,”Br. J. Canc. 68: 862-867 (1993).
Lazer, E. S., et al. “Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action,”J. Med. Chem. 37(7): 913-923 (1994).
Li, et al. “An Atherogenic Diet Rapidly Induces VCAM-1, a Cytokine-Regulatable Mononuclear Leukocyte Adhesion Molecule in Rabbit Aortic Endothelium,”Arteriosclr. Thromb. 13: 197-204 (1993).
Ma, D., et al. “Accelerating Effect Induced by the Structure of α-Amino Acid in the Copper Catalyzed Coupling Reaction of Aryl Halides with α-Amino Acids. Synthesis of Benzolactam-V8,”J. Am. Chem. Soc. 120(48): 12459-12467 (1998).
Marr-Leisy, et al.Colloid and Polymer Sc. 263(10): 791-798 (1985). Chem. Abstract 105: 97885.
Mulligan, et al. “Role of β1, β1 Integrins and ICAM-1 in Lung Injury after Deposition of IgG and IgA Immune Complexes,”Immunology150: 2407-2417 (1993).
Ohta, et al.Heterocylces31(9): 1655-1662 (1990). Chem. Abstract 114: 101454-1991:101454.
Ohta, et al.Chem.&Pharmaceutical Bulletin27(12): 2980-2987 (1979). Chem. Abstract 93: 46584-1980: 446584.
Okahara, et al. “Involvement of Very Late Activation Antigen 4 (VLA-4) and Vascular Cell Adhesion Molecule 1 (VCAM-1) in Tumor Necrosis Factor a Enhancement of Experimental Metastasis,”Can. Res. 54: 3233-3236 (1994).
Osborn. “Leukocyte Adhesion to Endothelium in Inflammation,”Cell62: 3-6 (1990).
Paavonen, et al.“In Vivo Evidence of the Role fo &#
Dressen Darren B.
Grant Francine S.
Konradi Andrei W.
Pleiss Michael A.
Semko Christopher
Elan Pharmaceuticals Inc.
Rao Deepak
LandOfFree
Heteroaryl, heterocyclic and aryl compounds which inhibit... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heteroaryl, heterocyclic and aryl compounds which inhibit..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heteroaryl, heterocyclic and aryl compounds which inhibit... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3626823